Serum MMP-9 level associated with initiation and progression steps of breast cancer in the Iranian population

Reproductive Sciences

Volumn 17, Issue 6, 2010, Pages 585-589

  Motovali Bashi, Majid ^a   Sadeghi, Morteza ^a   Hemmati, Simin ^b  

^a UNIVERSITY OF ISFAHAN   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Matrix metalloproteinase 9; Serum MMP 9 level

Indexed keywords

GELATINASE B;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST SURGERY; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PRIORITY JOURNAL; TUMOR VOLUME; ZYMOGRAPHY;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IRAN; MATRIX METALLOPROTEINASE 9; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 77952408476     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719110364418     Document Type: Article

References (31)

1. Nagase H., Woessner JF Matrix metalloproteinases. J Biol Chem. 1999 ; 274 (31). 21491-21494.
2. la-aho R., Kahari VM Collagenases in cancer. Biochimie. 2005 ; 87 (3-4). 273-286.
3. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000 ; 10 (6). 415-433.
4. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002 ; 2 (3). 161-174.
5. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999 ; 31 (1). 34-45.
6. Zucker S., Hymowitz M., Conner C., et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clin Exp Appl. 1999 ; 878: 212-227.
7. Rocca G., La Pucci-Minafra I., Marrazzo V., Taormina V., Minafra V. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer. 2004 ; 90: 1414-1421.
8. Chun-Ying W., Ming-Shiang W., En-Pei C., et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res. 2007 ; 13 (7). 2054-2060.
9. Hoikkala S., Paakko P., Soini Y., Makitaro R., Kinnula V., Turpeenniemi-Hujanen T. Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in stage I-III lung carcinoma. Cancer Lett. 2005 ; 236 (1). 125-132.
10. Ruokolainen H., Paakko P., Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer. 2005 ; 116 (3). 422-427.
11. Hayasaka A., Suzuki N., Fujimoto N., et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology. 1996 ; 24 (5). 1058-1062.
12. Leeman MF, Curran S., Murray GI New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol. 2003 ; 201 (4). 528-534.
13. Barbara S., Dieter P., Kathrin H., et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001 ; 7 (8). 2396-2404.
14. Duffy MJ, Maguire TM, Hill A., McDermott E., OHiggins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000 ; 2 (4). 252-257.
15. Leeman MF, Curran S., Murray GI New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol. 2003 ; 201 (4). 528-534.
16. Ranuncolo SM, Armanasco E., Cresta C., Bal De Kier Joffe E., Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer. 2003 ; 106 (5). 745-751.
17. Fernandez-Patron C., Martinez-Cuesta MA, Salas E., et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost. 1999 ; 82 (6). 1730-1735.
18. Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem. 2003 ; 49 (2). 339-340.
19. Makowski GS, Ramsby ML Calibrating gelatin zymograms with human gelatinase standards. Anal Biochem. 1996 ; 236 (2). 353-356.
20. Globacan. Cancer Incidence, Mortality and Prevalance Worldwide. Lyon, France: IARC Press ; 2000.
21. vant Veer LJ, Dai H., van de, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002 ; 415 (6871). 530-535.
22. King J., Zhao J., Clingan P., Morris D. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res. 2003 ; 23 (1B). 639-645.
23. Garbisa S., Scagliotti G., Masiero L., et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 1992 ; 52 (16). 4548-4549.
24. Zucker S., Lysik RM, Zarrabi MH, Moll U. M(r) 92 000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993 ; 53 (1). 140-146.
25. Hayasaka A., Suzuki N., Fujimoto N., et al. Elevated plasma levels of matrix metalloproteinase-9 92-kD type IV collagenasegelatinase B in hepatocellular carcinoma. Hepatology. 1996 ; 24 (5). 1058-1062.
26. Endo K., Maehara Y., Baba H., et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res. 1997 ; 17 (3C). 2253-2258.
27. Yang SF, Hsieh YS, Lin CL, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta. 2005 ; 354 (1-2). 91-99.
28. Decock J., Hendrickx W., Wildiers H., et al. Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clin Exp Metastasis. 2005 ; 22 (6). 495-502.
29. Somiari SB, Shriver CD, Heckman C., et al. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at high risk of developing breast cancer. Cancer Lett. 2006 ; 233 (1). 98-107.
30. Nikkola J., Vihinen P., Vuoristo MS, Kellokumpu-Lehtinen P., Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res. 2005 ; 11 (14). 5158-5166.
31. Hanemaaijer R., Verheijen JH, Maguire TM, et al. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer. 2000 ; 86 (2). 204-207.